Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization

• Published in: Canadian journal of ophthalmology 2012-06, Vol.47 (3), p.269-274
• Main Authors: Mansour, Ahmad M., MD, Arevalo, J. Fernando, MD, FACS, Fardeau, Christine, MD, Hrisomalos, Emily N., BS, Chan, Wai-Man, FRCP, FRCOphth, MBBS, Lai, Timothy Y.Y., MD, FRCS, Ziemssen, Focke, MD, Ness, Thomas, MD, Sibai, Abla Mehio, PhD, Mackensen, Friederike, MD, Wolf, Armin, MD, Hrisomalos, Nicholas, MD, Heiligenhaus, Arnd, MD, Spital, Georg, MD, Jo, Yukari, MD, Gomi, Fumi, MD, Ikuno, Yasushi, MD, Akesbi, Jad, MD, LeHoang, Phuc, MD, Adan, Alfredo, MD, Mahendradas, Padmamalini, DO, DNB, Khairallah, Moncef, MD, Guthoff, Rainer, MD, Ghandour, Blanche, BS, Küçükerdönmez, Cem, MD, Kurup, Shree K., MD
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Angiogenesis Inhibitors - administration & dosage; Antibodies, Monoclonal, Humanized - administration & dosage; Bevacizumab; Chemotherapy, Adjuvant; Child; Choroidal Neovascularization - drug therapy; Choroidal Neovascularization - physiopathology; Choroiditis - drug therapy; Choroiditis - physiopathology; Female; Humans; Immunosuppressive Agents - therapeutic use; Internal Medicine; Intravitreal Injections; Male; Middle Aged; Ophthalmology; Retina - pathology; Retrospective Studies; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Uveitis - drug therapy; Uveitis - physiopathology; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity - physiology
• ISSN: 0008-4182; 1715-3360
• DOI: 10.1016/j.jcjo.2012.03.042

Abstract Objective To assess the 3-year visual outcome of intravitreal bevacizumab in inflammatory ocular neovascularization. Design Experimental study. Methods Retrospective multicenter consecutive case series in 81 patients with inflammatory ocular neovascularization refractory to standard therapy and treated with intravitreal bevacizumab. The outcome measures included improvement of best corrected visual acuity expressed as logarithm of minimum angle of resolution (logMAR) and paired comparison decrease in central foveal thickness by optical coherence tomography. Results Mean best corrected visual acuity improved from baseline 0.699 (6/30 or 20/101) (SD 0.434) to 0.426 (6/16 or 20/53) (SD 0.428) (n = 81; p < 0.001), a gain of 2.7 lines (median 3 injections; 81 eyes; 81 patients). Paired comparisons revealed significant central foveal flattening at 3 years of 97.9 μm (n = 51; p < 0.001). In a subgroup analysis, visual improvement was significant for ocular histoplasmosis ( p = 0.026); multifocal choroiditis ( p = 0.05); serpiginous choroiditis ( p = 0.028); ocular toxoplasmosis ( p = 0.042); and punctate inner choroidopathy ( p = 0.015). In a subgroup analysis, foveal flattening was significant for ocular histoplasmosis ( p = 0.004); multifocal choroiditis ( p = 0.007); serpiginous choroiditis ( p = 0.011); and punctate inner choroidopathy ( p = 0.001). Of the group, 5 eyes developed submacular fibrosis, 1 eye retinal pigment epithelial tear, and 1 eye macular ischemia in the context of vasculitis. Conclusion At 3 years, intravitreal bevacizumab sustained significant visual improvement of 2.7 lines and significant foveal flattening of 98 μm in a wide variety of inflammatory ocular diseases without major complications after a median of 3 injections.